NeuroSense Therapeutics (NRSNW) Expected to Announce Quarterly Earnings on Wednesday

NeuroSense Therapeutics (NASDAQ:NRSNW) is projected to announce its results before the market opens on Wednesday, September 2nd. Analysts expect NeuroSense Therapeutics to post earnings of ($0.1950) per share and revenue of $0.2680 million for the quarter.

NeuroSense Therapeutics Price Performance

NASDAQ:NRSNW opened at $0.07 on Tuesday. The company’s 50 day moving average is $0.10 and its 200-day moving average is $0.14. NeuroSense Therapeutics has a 12 month low of $0.04 and a 12 month high of $0.70.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.